Q301--Lab Testing Services - clonoSEQ Measurable Residual Disease Test Pittsburgh VA Medical Center - Pittsburgh, PA
Inactive on SAM.gov — responses were due 10 Aug 2026 · Unrestricted (full and open) · Department of Veterans Affairs (VA) · NAICS 621511 · Solicitation 36C24426Q0855
Following NAICS 621511? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 10 August 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 621511 (Medical Laboratories) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
NOTICE OF INTENT TO AWARD SOLE SOURCE: The Department of Veterans Affairs (VA) Regional Procurement Office East (RPOE), Network Contracting Office 4 (NCO 4) intends to award a sole source contract pursuant to RFO FAR 6.103-1 to Adaptive Biotechnologies Corporation located at 1165 Eastlake AVE E, Seattle, Washington 98109. Simplified acquisition procedures will be used, and the resulting contract will be firm priced for a five-year period. The Pittsburgh VA Medical Center requires a contractor to provide clonoSEQ Measurable Residual Disease (MRD) Testing. This service shall be provided for the Department of Veterans Affairs, Pittsburgh VA Medical Center, located at University Drive, Pittsburgh, PA 15240. The clonoSEQ assay is provided exclusively by Adaptive Biotechnologies and is a proprietary, FDA-cleared, patented molecular test developed and performed exclusively by Adaptive Biotechnologies for MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL), and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). It is also a CLIA-validated laboratory developed (LDT) test for diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies. Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet the VA facility s needs. Line Item Description Annual Quantity 1 ClonoSEQ MRD Testing 100 THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE QUOTES; however, any responsible firm that believes it can meet the requirement shall give written notification and capability statements prior to the response due date and time. Vendors shall indicate if they are the direct supplier or service provider of the items and/or authorized reseller/distributor. Supporting evidence shall be furnished in sufficient detail to demonstrate the ability to perform the requirement and shall include relevant experience along with the applicable contract number(s), total contract dollar amount, contract period of performance, details of the relevant supply and/or services, and customer point of contact with corresponding telephone number and email address. Responses shall include following information: 1. Company Name 2. SAM UEI Number 3. Company s Address 4. Point of Contact Information (title, phone number and email address) 5. Business Size Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based on responses to this notice is solely within the discretion of the Government. Information provided will not be returned. Responses are due by Monday, 8/10/2026 at 8:00 AM Eastern Standard Time. No submissions will be accepted after this date and time. Responses shall be submitted via email to Mrs. Mickeya Linzie at mickeya.linzie@va.gov. The NAICS code for this acquisition is 621511 (Medical Laboratories) and the size standard is $41.5 million.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
